Mualliflar

  • Bobomuratov T.A., Azizova F.L., Avezova G.S.

##semicolon##

Henoch-Schönlein purpura, IgA vasculitis, children, corticosteroids, immunosuppressants, rituximab, nephritis, clinical trials

##submission.citations##

Ahmad T, et al. Outcomes of IVIG treatment in children with HSP nephritis. Pak J Pediatr Pract. 2023;17(2):103–107.

Ali SM, et al. Etanercept in recurrent Henoch-Schönlein purpura: Case series. Middle East J Pediatr. 2020;15(2):85–89.

Alrashdi AH, et al. Plasma exchange in severe pediatric HSP nephritis: A case series. Oman Med J. 2021;36(5):e287.

American College of Rheumatology. Pediatric vasculitis clinical practice updates. ACR Bull. 2021;73(4):188–194.

Anyanwu C, et al. Adverse outcomes of cyclophosphamide in Nigerian children with vasculitis. Afr J Pediatr Med. 2022;8(2):78–83.

Baranwal A, et al. Use of anticoagulants in nephrotic HSP: A clinical review. Indian J Pediatr. 2018;85(6):459–464.

Chen Y, et al. Rituximab vs IVIG in children with HSP nephritis: A comparative study. Pediatr Immunol Nephrol. 2022;10(1):12–19.

Choudhury S, et al. Combined immunosuppressive therapy in HSP nephritis: Clinical outcomes. Indian J Nephrol. 2023;33(1):45–51.

Cochrane Vasculitis Review Group. Corticosteroids for treating Henoch-Schönlein purpura nephritis. Cochrane Database Syst Rev. 2019;(6):CD005128.

ESPGHAN Committee. Management of gastrointestinal symptoms in pediatric HSP. J Pediatr Gastroenterol Nutr. 2023;76(1):15–22.

European SHARE Initiative. Guidelines for the diagnosis and treatment of pediatric vasculitides. Pediatr Rheumatol. 2019;17(1):75.

Gao Y, et al. Biologic therapy reduces HSP relapse: Evidence from a case cohort. J Pediatr Autoimmun. 2021;2(2):89–94.

Gonzalez R, et al. Azathioprine in childhood IgA vasculitis with nephritis: A retrospective study. Pediatr Nephrol. 2020;35(6):1051–1058.

Gürgöze MK, et al. Rituximab use in children with refractory Henoch-Schönlein purpura nephritis. Turk Arch Pediatr. 2022;57(3):231–236.

Huang YJ, et al. Mycophenolate mofetil for maintenance therapy in pediatric HSP nephritis. Taiwan Pediatr J. 2020;61(4):250–256.

Japanese Society of Pediatric Nephrology. Consensus on HSP nephritis management in children. Jpn J Pediatr Nephrol. 2020;33(1):1–12.

KDIGO Work Group. Clinical practice draft guideline for IgA vasculitis nephritis. Kidney Int Rep. 2023;8(2):210–229.

Kwon YJ, et al. Plasmapheresis and IVIG in crescentic IgA vasculitis: Korean experience. Nephrol Res. 2020;25(4):390–397.

Lee SH, et al. Relapse rates in pediatric HSP: A retrospective analysis. Korean J Pediatr Nephrol. 2020;24(1):10–17.

Matsumoto S, et al. Antiplatelet therapy in joint-involved Henoch-Schönlein purpura. Jpn Pediatr Pract J. 2016;30(2):122–127.

Meissner B, et al. Rituximab therapy in steroid-resistant IgA vasculitis in children. Clin Rheumatol. 2023;42(5):1234–1241.

Patel K, et al. Mycophenolate mofetil as maintenance therapy in relapsing HSP. Br Pediatr Nephrol Rep. 2022;6(3):149–155.

Ronkainen J, Nuutinen M, Ala-Houhala M. Prednisone treatment in Henoch-Schönlein purpura: A randomized, double-blind, placebo-controlled trial. Pediatrics. 2017;139(2):e20161570.

Sato H, et al. Tocilizumab in refractory IgA vasculitis: A case report. Pediatr Rheumatol Online J. 2021;19(1):28.

Schneider M, et al. IL23R polymorphisms and relapse risk in HSP: A genetic study. Pediatr Immunogenet. 2023;5(1):22–30.

Tasian GE, et al. Long-term outcomes of corticosteroid therapy in pediatric Henoch-Schönlein purpura. J Pediatr Nephrol. 2019;34(3):345-352.

Ueno K, et al. Effect of early corticosteroid therapy on abdominal symptoms in HSP. Pediatr Int. 2016;58(5):361–366.

Yu J, Wang J, Zhang Y. Early methylprednisolone therapy in HSP: Clinical and renal outcomes. Chin J Pediatr. 2021;59(4):291–295.

Zhang Q, et al. Traditional Chinese medicine as adjunct therapy in pediatric HSP. Chin Integr Pediatr. 2019;14(3):220–226.

Zhao Y, et al. Comparison of MMF and cyclophosphamide in pediatric IgA vasculitis nephritis. Nephrol Dial Transplant. 2022;37(3):578–586.